drugset / Trial / NCT00410488
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
RandomizedSingle-groupOpen-labelSupportive care
Summary
The goal of this clinical research study is to compare 2 treatment schedules of Aloxi (palonosetron) in patients with sarcoma who are receiving chemotherapy with adriamycin and ifosfamide. The safety of the drug and schedules will be studied. The effect of palonosetron on patients' quality of life (QOL) will also be studied.
Timeline
- Start
- 2006-12
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
| Comparator | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 1500 mg/m2 | Intravenous |
| Comparator | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Comparator | Dexrazoxane | Small molecule | 750 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Comparator | Ifosfamide | Small molecule | 2.5 g/kg | Intravenous |
| Comparator | Vincristine | Small molecule | 2 mg | Intravenous |